Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11033565 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(24 days from now) | |
US8815816 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(24 days from now) | |
US8093219 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(24 days from now) | |
US8080530 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(24 days from now) | |
US8415311 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(24 days from now) | |
US8470788 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(24 days from now) | |
US7550440 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(24 days from now) | |
US9233118 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(9 years from now) | |
US10206939 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(9 years from now) | |
US9089587 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(9 years from now) | |
US9233117 | GALDERMA LABS LP | Treatment of inflammatory lesions of rosacea with ivermectin |
Mar, 2034
(9 years from now) | |
US9782425 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(9 years from now) |
Soolantra is owned by Galderma Labs Lp.
Soolantra contains Ivermectin.
Soolantra has a total of 12 drug patents out of which 0 drug patents have expired.
Soolantra was authorised for market use on 19 December, 2014.
Soolantra is available in cream;topical dosage forms.
Soolantra can be used as treatment of inflammatory lesions of rosacea..
The generics of Soolantra are possible to be released after 13 March, 2034.
Drugs and Companies using IVERMECTIN ingredient
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of inflammatory lesions of rosacea.
Dosage: CREAM;TOPICAL